6-hydroxy-3-(phenylcarbonyl)-2H-chromen-2-one | 1334616-19-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-hydroxy-3-(phenylcarbonyl)-2H-chromen-2-one
• 英文别名: 3-benzoyl-6-hydroxy-2H-chromen-2-one；3-Benzoyl-6-hydroxychromen-2-one
• CAS: 1334616-19-1
• 化学式: C₁₆H₁₀O₄
• 分子量: 266.253
• InChiKey: LFABXJTUEHBFNF-UHFFFAOYSA-N

物化性质

• 熔点：
  224-225 °C
• 沸点：
  524.9±50.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-hydroxy-3-(phenylcarbonyl)-2H-chromen-2-one 、 苯肼 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以0.093 g的产率得到(±)-5-(2',5'-dihydroxyphenyl)-N',1,3-triphenyl-4,5-dihydro-1H-pyrazole-4-carbohydrazide
  参考文献：
  名称：

  具有双重活性的二氢吡唑-碳酰肼衍生物作为靶向 HDAC6 的乳腺癌的抗氧化和抗增殖药物

  摘要：

  乳腺癌 (BC) 是最常被诊断出的癌症，也是全球女性第二大常见死因。正因为如此，寻找治疗 BC 的新药和靶向疗法是一项紧迫的全球需求。组蛋白去乙酰化酶 6 (HDAC6) 是一种很有前途的抗 BC 药物靶点，与其发展和进展有关。在目前的工作中，提出了专注于 HDAC6 抑制活性的二氢吡唑-甲酰肼衍生物 (DPCH) 衍生物的新家族的设计和合成。计算化学方法用于合理化设计并评估其物理化学和毒理学特性。合成并表征了九个DPCH的新家族。化合物表现出最佳的物理化学和毒理学特性，可作为人类药物的潜在应用。计算机研究表明，与参考化合物一样，具有 -Br、-Cl 和 -OH 取代基的化合物与 HDAC6 的催化域 2 具有良好的亲和力。在 MCF-7 和 MDA-MB-231 BC 细胞系上测定了九种 DPCH 衍生物，显示出具有 IC 的抗增殖活性在微米范围内为50 。在体外，化合物2b对人 HDAC6

  DOI：

  10.3390/ph15060690
• 作为产物：
  描述：

  3-benzoyl-6-methoxy-2H-chromen-2-one 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 6-hydroxy-3-(phenylcarbonyl)-2H-chromen-2-one
  参考文献：
  名称：

  Synthesis and Electrochemical and Biological Studies of Novel Coumarin–Chalcone Hybrid Compounds

  摘要：

  A series of novel hydroxy-coumarin chalcone hybrid compounds 2a-i has been synthesized by employing a simple and efficient methodology. An electrochemical characterization using cyclic voltammetry and ESR spectroscopy were carried out to characterize the oxidation mechanism for the target compounds. The antioxidant capacity and reactivity were determined by ORAC and ESR assays, respectively. Biological assays were assessed to evaluate the cytotoxicity and cytoprotection capacity against ROS/RNS on BAEC. The results revealed that all tested compounds present ORAC values that are much higher than other well-known antioxidant compounds such as quercetin and catechin. Compound 2e showed the highest ORAC value (14.1) and also presented a low oxidation potential, good scavenging capacity against hydroxyl radicals, low cytotoxicity, and high cytoprotective activity.

  DOI：

  10.1021/jm400546y

文献信息

• Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives
  作者：Daniela Secci、Simone Carradori、Adriana Bolasco、Paola Chimenti、Matilde Yáñez、Francesco Ortuso、Stefano Alcaro

  DOI：10.1016/j.ejmech.2011.07.017

  日期：2011.10

  Several 3-carbonyl (1–26), 3-acyl (27–52), and 3-carboxyhydrazido (53–58) coumarins have been synthesized in high yields (72–99%) and tested in vitro for their human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitory activity. Different substituents on the coumarin nucleus were evaluated for their effect on biological activity and isoform selectivity. Substitution at position C7 of the 3-ethyl

  几个-3-羰基（1 - 26），3-酰基（27 - 52），和3- carboxyhydrazido（53 - 58）香豆素已经以高收率（72-99％）合成并测试在体外对它们的人类单胺氧化酶A和B（hMAO-A和hMAO-B）的抑制活性。评价了香豆素核上的不同取代基对生物活性和同工型选择性的影响。对于使用IC 50获得高效且选择性的hMAO-B抑制剂而言，在3-乙酯香豆素环的C7位取代或在C3引入肼基取代基很重要。值在纳摩尔范围内。一些衍生物也进行了稳定性测试，在体外没有化​​学裂解。
• ROS Inhibitory Activity and Cytotoxicity Evaluation of Benzoyl, Acetyl, Alkyl Ester, and Sulfonate Ester Substituted Coumarin Derivatives
  作者：Uzma Salar、Khalid M. Khan、Almas Jabeen、Aisha Faheem、Farwa Naqvi、Shakil Ahmed、Erum Iqbal、Farman Ali、Kanwal、Shahnaz Perveen

  DOI：10.2174/1573406415666190826153001

  日期：2020.11.23

  Limited SAR study revealed that the hydroxy-substituted compound showed better ROS inhibition potential in case of 3-benzoyl and 3-ethylester coumarin derivatives. Whereas, chloro substitution was found to be important in case of 3-acetyl coumarin derivatives. Similarly, in case of sulfonate ester, chloro, and nitro groups especially at positions -4 and -3 of ring "R" played vital role in ROS inhibition

  背景许多非甾体抗炎药(NSAID)，包括阿司匹林、消炎痛、布洛芬、氟芬那酸和保泰松在临床上用于治疗炎性疾病。这些非甾体抗炎药与严重的副作用有关，例如胃溃疡、肾毒性和出血。因此，确定有效和安全的炎症性疾病治疗方法仍然是药物化学家非常感兴趣的。方法 使用鲁米诺增强化学发光技术筛选了一系列不同取代的苯甲酰基、乙酰基、烷基酯和磺酸酯取代的香豆素 1-64 对活性氧的抑制作用，活性氧是由酵母聚糖激活的全血吞噬细胞产生的。结果 在所有测试化合物中，8 (IC50 = 65.0 ± 3.1 μM)、24 (IC50 = 41.8 ± 1.5 μM)、26 (IC50 = 10.6 ± 2.8 μM)、28 (IC50 = 20。9 ± 1.5 μM)和 41 (IC50 = 4.6 ± 0.3 μM) 与标准抗炎药布洛芬 (IC50 = 54.3 ± 1.9 μM) 相比显示出良好的抗炎潜力。具体而言，化合物
• Coumarin Derivatives Act as Novel Inhibitors of Human Dipeptidyl Peptidase III: Combined In Vitro and In Silico Study
  作者：Dejan Agić、Maja Karnaš、Domagoj Šubarić、Melita Lončarić、Sanja Tomić、Zrinka Karačić、Drago Bešlo、Vesna Rastija、Maja Molnar、Boris M. Popović、Miroslav Lisjak

  DOI：10.3390/ph14060540

  日期：——

  underscores the need to find new hDPP III inhibitors. In this research, five series of structurally different coumarin derivatives were studied to provide a relationship between their inhibitory profile toward hDPP III combining an in vitro assay with an in silico molecular modeling study. The experimental results showed that 26 of the 40 tested compounds exhibited hDPP III inhibitory activity at a concentration

  二肽基肽酶 III (DPP III) 是一种锌依赖性外肽酶，是金属蛋白酶家族 M49 的成员，几乎在所有生命形式中都能检测到其分布。尽管人类 DPP III (hDPP III) 的生理作用尚未完全阐明，但其参与病理生理过程，如哺乳动物疼痛调节、血压调节和癌症过程，强调需要寻找新的 hDPP III 抑制剂。在这项研究中，研究了五个系列结构不同的香豆素衍生物，以提供它们对 hDPP III 的抑制特性之间的关系，结合体外测定和计算机分子建模研究。实验结果表明，40 种测试化合物中有 26 种在 10 µM 浓度下表现出 hDPP III 抑制活性。化合物12(3-benzoyl-7-hydroxy-2H-chromen-2-one) 被证明是最有效的抑制剂，IC 50值为 1.10 μM。QSAR 模型表明香豆素衍生物上具有双键和三键以及芳香羟基的较大取代基的存在会增加它们的抑制活性。对接预测12与
• Anti-MRSA (Multidrug Resistant Staphylococcus aureus) Activity of 3-Substituted Coumarins
  作者：Uzma Salar、Khalid Mohammed Khan、Humaira Muhammad、Muhammed Imran Fakhri、Sanaullah、Shahnaz Perveen、Muhammed Iqbal Choudhary

  DOI：10.2174/1570180814666170619121844

  日期：2018.3.12

  Background: Infectious pathogenic bacteria are the key virulence in our daily life. Especially diseases produced by multidrug resistant Staphylococcus aureus (MRSA) still contributing in morbidity and mortality in humans. Discovery of new and safer antibiotics is an upmost task in current medicinal research. Methods: By keeping in mind the considerable antimicrobial activities of coumarin scaffold, 3-substituted coumarin derivatives 1-24 were synthesized by Knoevenegel condensation reaction. Different aryl aldehydes were treated with β-keto esters in the presence of organic base piperidine. All synthetic compounds were characterized by different spectroscopic techniques such as EI-MS, HREI-MS, 1H-NMR, and 13C-NMR. Compounds were screened to check for their in vitro anti- MRSA (multidrug resistant Staphylococcus aureus) activity against different strains of bacteria such as MRSA-252, EMRSA-16, EMRSA-17 and local clinical isolate. Micro-plate alamar blue assay (MABA) was used for this activity. Oxacillin, streptomycin, clindamycin and vancomycin were used as standards. Results: Results were reported as percent inhibition at 20 µg/mL concentration. Amongst all four standard drugs, only vancomycin was showed 19%, 24%, 21% and 40% inhibitions in case of MRSA-252, EMRSA-16, EMRSA-17 and local clinical isolate, respectively, at 20 µg/mL concentration. Most of the synthetic compounds were showed a weak to good inhibition as compared to standard, vancomycin. Conclusion: Newly identified compounds may serve as lead for future research in order to get the more powerful antibacterial agents.

  背景：传染性病原菌是我们日常生活中的主要致病菌。特别是由耐多药金黄色葡萄球菌（MRSA）引起的疾病仍然是人类发病和死亡的主要原因。发现新的、更安全的抗生素是当前药物研究的首要任务。 方法：考虑到香豆素支架具有相当高的抗菌活性，研究人员通过 Knoevenegel 缩合反应合成了 3-取代香豆素衍生物 1-24。 在有机碱哌啶存在下，不同的芳基醛与β-酮酯进行了处理。 所有合成化合物均通过不同的光谱技术（如 EI-MS、HREI-MS、1H-NMR 和 13C-NMR）进行了表征。对化合物进行了体外抗 MRSA（耐多药金黄色葡萄球菌）活性筛选，以检测其对不同菌株（如 MRSA-252、EMRSA-16、EMRSA-17 和本地临床分离菌株）的活性。该活性采用了微孔板金蓝分析法（MABA）。结果：结果以 20 µg/mL 浓度时的抑制百分率报告。在所有四种标准药物中，只有万古霉素在 20 µg/mL 浓度下对 MRSA-252、EMRSA-16、EMRSA-17 和本地临床分离物的抑制率分别为 19%、24%、21% 和 40%。 与标准药物万古霉素相比，大多数合成化合物的抑制率从弱到强。 结论：新发现的化合物可作为一种新的抗生素：新发现的化合物可作为未来研究的线索，以获得更强的抗菌剂。
• US4199363A
  申请人：——

  公开号：US4199363A

  公开（公告）日：1980-04-22